Metabolic Disease Incidence After Allogeneic Stem Cell Transplantation: A Nationwide Korean Case-Control Study.

Jeonghoon HaSee Hyun ParkSung Soo Park Seunghoon Han

Published in: The Journal of clinical endocrinology and metabolism (2022)

Recipients of allo-HSCT need to be rigorously monitored for the development of metabolic diseases, including hypertension, diabetes, dyslipidemia, and CVA, based on an enhanced lifelong health care policy including a robust screening program compared to the general population.

Keyphrases

stem cell transplantation
healthcare
high dose
blood pressure
type diabetes
cardiovascular disease
public health
risk factors
quality improvement
low dose
hematopoietic stem cell
glycemic control
cross sectional
kidney transplantation
social media